CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Nintedanibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03062943
NCT03062943Phase 2Completed
CompareCT.gov

A Pilot Study of Nintedanib for LymphAngioleioMyomatosis (LAM)

IRCCS Multimedica·interventional·Posted Feb 24, 2017·Updated Sep 28, 2022

In Brief

A Phase 2 clinical trial evaluating Nintedanib for Lymphangioleiomyomatosis. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This trial is conducted locally. The aim of this trial is assess the efficacy and a favorable benefit-risk ratio for nintedanib in the treatment of LAM at the dose of 150 mg bid

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphangioleiomyomatosis
CountriesItaly
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 24, 2017
Enrollment StartDec 6, 2016
Primary CompletionDec 1, 2021
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 9.4 years ago

Interventions

Nintedanibdrug